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c-Synuclein Interacts with Phospholipase Cb2 to
Modulate G Protein Activation
Urszula Golebiewska1,2, Yuanjian Guo1, Narindra Khalikaprasad1, Cassandra Zurawsky1, V.
Siddhartha Yerramilli1, Suzanne Scarlata1*
1 Department of Physiology & Biophysics, Stony Brook University, Stony Brook, New York, United States of America, 2 Department of Biological Sciences and Geology,
Queensborough Community College, Bayside, New York, United States of America

Abstract
Phospholipase Cb2 (PLC b2) is activated by G proteins and generates calcium signals in cells. PLCb2 is absent in normal
breast tissue, but is highly expressed in breast tumors where its expression is correlated with the progression and migration
of the tumor. This pattern of expression parallels the expression of the breast cancer specific gene protein 1 which is also
known as c-synuclein. The cellular function of c-synuclein and the role it plays in proliferation are unknown. Here, we
determined whether c-synuclein can interact with PLCb2 and affect its activity. Using co-immunprecitation and coimmunofluorescence, we find that in both benign and aggressive breast cancer cell lines c-synuclein and PLCb2 are
associated. In solution, purified c-synuclein binds to PLCb2 with high affinity as measured by fluorescence methods.
Protease digestion and mass spectrometry studies show that c-synuclein binds to a site on the C-terminus of PLCb2 that
overlaps with the Gaq binding site. Additionally, c-synuclein competes for Gaq association, but not for activators that bind
to the N-terminus (i.e. Rac1 and Gbc). Binding of c-synuclein reduces the catalytic activity of PLCb2 by mechanism that
involves inhibition of product release without affecting membrane interactions. Since activated Gaq binds more strongly to
PLCb2 than c-synuclein, addition of Gaq(GTPcS) to the c-synuclein –PLCb2 complex allows for relief of enzyme inhibition
along with concomitant activation. We also find that Gbc can reverse c-synuclein inhibition without dissociating the csynuclein- PLCb2- complex. These studies point to a role of c-synuclein in promoting a more robust G protein activation of
PLCb2.
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Like c-synuclein, phospholipase C b2 (PLCb2) is absent in
normal breast tissue, but is highly expressed in transformed tissue
where its level of expression is directly related to tumor progression
and migration [10,11] presumably through its regulation by small
G proteins [10,11]. PLCb2 is a member of a larger mammalian
PLC family that catalyzes the hydrolysis of phosphatidylinositol
4,5 bisphosphate (PI(4,5)P2). Cleavage of PI(4,5)P2 generates the
second messengers, diacylglycerol and 1,4,5 inositol trisphosphate
(Ins(1,4,5)P3), which activate protein kinase C (PKC) and cause the
release of Ca2+ from intracellular stores, respectively. All four
isoforms of PLCb are strongly activated by Gaq. Additionally,
PLCb2 and PLCb3 are activated by Gßc dimers that can
potentially be released upon activation of all Ga families. It has
also been found that PLCb2 can be activated by members of the
Rho family of monomeric G proteins with the strongest activation
by Rac1, which is involved in the cytoskeletal rearrangements that
accompany cell mobility [12].
PLCb2 is a modular protein composed of an N-terminal
pleckstrin homology (PH) domain, 4 EF hands, a catalytic domain,
a C2 domain and a long C-terminal extension (see [13]).
Crystallographic studies have indicated that Rac1 may promote
enzyme activity by binding strongly to the PH domain and
promoting membrane binding [14]. Alternately, Gbc activates the

Introduction
The synucleins are small (,140 amino acid) proteins, that have
a weak homology to 14.3.3 proteins (a typical member of the
chaperone protein family (see [1,2,3]). The synucleins are
considered to be ‘‘natively unfolded’’ [4] although recent work
indicates that in cells a-synuclein folds into a dynamic tetramer
[5,6]. There are three members of the synuclein family, a, b and c
that are conserved and found throughout vertebrates. The cellular
function(s) of synucleins have not yet been discovered. aSynuclein, the most notable family member, is associated with
neurodegenerative plaques [2].
Although c-synuclein is found mostly in the peripheral nervous
system and in pre-synaptic terminals, its over-expression is
associated with cancer progression. c-Synuclein was identified as
the breast cancer specific gene protein 1 (BCSG1) ,10 years ago
by screening a breast cancer cDNA library [7]. c-Synuclein is
highly expressed in infiltrating breast cancer [8] but is undetectable in normal or benign breast lesions, and is partially expressed
in ductal carcinomas. While the function of c-synuclein is
unknown, it is found in a wide variety of transformed cells and
its overexpression leads to a significant increase in proliferation,
motility, invasiveness and metastasis [8,9].
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Sf9 cells and the heterotrimer was purified on a Ni2+-NTA
column, and then dissociated by activation with GTPcS [18]. The
purity of proteins was assessed by SDS-PAGE electrophoresis and
western blotting. Concentrations were determined by a Bradford
assay (BioRad) or on SDS-PAGE gels with known concentrations
of BSA for reference. His6-PLCb2 was expressed in Sf9 cells using
a baculovirus system with minor modifications [17]. A C-terminal
truncation mutant of PLCb2 used for some of the control studies is
a chimera of PLCb2 and PLCd1 described in [19]. Rac1 was
a generous gift from Dr. Nicolas Nassar (Univ. Cincinnati) and its
integrity was verified by SDS-PAGE electrophoresis and mass
spectrometry and was prenylated using a kit from Uniprot, Inc.

enzyme by simultaneously interacting with both the PH and
catalytic domains to change their domain orientation, while Gaq
activates the enzyme through interactions with the C2 and Cterminal regions of the enzyme (see [15]). Even though PLCb3 can
be simultaneously activated by Gaq and Gbc, this does not appear
to occur for PLCb2 [16].
Here, we have tested the idea that c-synuclein interacts with
PLCb2 to promote cancerous phenotypes. We present data
showing that they may associate in breast cancer cells and in
solution. The binding of c-synuclein to PLCb2 results in inhibition
of enzymatic activity that can be overcome by the addition of G
protein subunits. This relief of c-synuclein inhibition along with
activation results in a more robust response of the enzyme.

Digestion studies
m-Calpain digestion was carried out by adding m-calpain in
800 !M calcium to pre-incubated PLCß2- c-synuclein complexes, at 100 nM each, for 25uC for 20 minutes. The amount of
digestion was assessed by western blot analysis using anti-PLCb2
(Santa Cruz Biochemicals), or by assessing the loss in enzyme
activity as determined by the ability of 20–50 nM enzyme to
hydrolyze [3H]PI(4,5)P2 dispersed on 2 mM sonicated membranes
composed of phosphatidyl serine: phosphatidyl ethanolamine:
phosphatidyl inositol 4,5 bisphosphate (PS: PE: PI(4,5)P2) at
a 2:1:0.5 molar ratio as described previously [20].

Materials and Methods
Cell culture
MDA MB 231 cells were purchased from American Type
Culture Collection (ATCC) and were cultured in Dulbecco’s
Minimum Essential Media (DMEM) supplemented with 10%
Fetal Bovine Serum (FBS), 50 units/mL of penicillin and 50 mg/
mL of streptomycin at 37uC and 5% CO2. MCF 10 A cells, also
purchased from ATCC, were also cultured at 37uC and 5% CO2
in a medium that consists of 1:1 mixture of Ham’s F12 and
DMEM media supplemented with 10% FBS, 50 units/mL of
penicillin and 50 mg/mL of streptomycin, 10 mg/ml bovine
insulin, 0.18 mg/ml hydrocortisone, and 20 ng/ml recombinant
human epidermal growth factor.

Mass spectrometry
PLCb2 bands alone or subjected to calpain digestion were
isolated on SDS PAGE electrophoresis. The bands were cut and
removed, digested by trypsin and the peptides were analyzed by
LC/MS/MS on a Thermo LTQ XL at the Proteomics Center at
Stony Brook University.

Immunofluorescence
Cells were fixed using 3.7% formaldehyde and permeabilized
with 0.2% nonyl phenoxypolyethoxylethanol (NP40) and incubated with 0.2% NP40 in phosphate buffered saline (PBS) for
5 min and then blocked in PBS containing 4% goat serum for 1 h.
The cells were then incubated with the primary antibody (antiPLCb2 (Santa Cruz Biochemicals, Inc.) and anti-c-synuclein
(Abcam, Inc.)) diluted to 1:500 overnight at 4uC, followed by
incubation with Alexa-labeled secondary antibody for 1.5 hours at
room temperature. The cells were washed with tris buffered saline
(TBS) buffer after the incubations. Images of the cells were
obtained using Olympus Fluoview FV1000 laser scanning confocal
microscope, and were analyzed using Olympus (Fluoview)
software and Image J (NIH).

Enzyme Activity Studies
Measurements of PI(4,5)P2 hydrolysis by PLC enzymes were
carried out by doing small, unilamellar vesicles composed of 1palmitoyl -2 –oleoyl phosphatidylethanolamine (PE): 1-palmitoyl2-oleoyl phosphatidyl serine (PS) :PI(4,5)P2 at a 66:32:2 molar
ratio with enough [3H]PI(4,5)P2 to achieve reliable signal(see [21]).

Fluorescence labeling and titrations
Proteins were labeled on ice with the thiol-reactive probe7diethylamino-3-(49-maleimidylphenyl)-4-methylcoumarin (CPM)
or Dabcyl at a probe:protein ratio of 4:1. The reaction was
stopped after 60 minutes by adding 10 mM DTT and the protein
was purified either by extensive dialysis or using a PD G-25 spin
trap column (GE Healthcare).
Fluorescence measurements were performed on an ISS
spectrofluorometer (Champaign, IL) using 3 mm quartz cuvettes.
Peptide and protein stocks were diluted into 20 mM Hepes
(pH 7.2), 160 mM NaCl, 1 mM DTT. The emission spectrum of
CPM-labeled protein was measured from 400 to 550 nm
(lex = 380 nm). The background spectra of unlabeled protein or
peptide were subtracted from each spectrum along the titration
curve. All of the spectra were corrected for the 10–12% dilution
that occurred during the titration.

Co-immunoprecipiation
MDA MB 231 cells were lysed with 500 ul of buffer containing
150 mM NaCl, 20 mM HEPES, 2 mM MgCl2, 5 mM 2mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, 10 ug/
ml leupeptin and 10ug/ml aprotinin. The lysate was then added to
20 ml of Protein A beads, which were incubated with 5 ml of rabbit
anti-c synuclein antibody overnight at 4uC, and the mixture was
gently rotated for 4 hours at 4uC. The unbound proteins were
separated from the beads, which were then washed twice with the
lysis buffer. The bound proteins were then eluted from the beads
in sample buffer at 95uC for 3 minutes and were loaded onto
a 12% PAGE gel along with an equal volume of the unbound
proteins for SDS-PAGE. After western transfer to polyvinylidene
difluoride membranes, the membranes were blotted with anti- csynuclein and anti-PLCb2 antibodies.

Results
c-Synuclein and PLCb2 associate in breast cancer cells
As an initial step in understanding the relationship between csynuclein and PLCb2 in breast cancer, we determined whether
these proteins associate in cells. We first visualized their cellular
localization and colocalization in two cultured breast cancer
epithelial cell lines, MCF10A representing stage 1 cancer, and

Protein expression and purification
Human c-synuclein was expressed and purified using an
identical procedure as described for a-synuclein [17] with minor
modifications. Gb1 and His6-Gc2 were co-expressed with Gaq in
PLoS ONE | www.plosone.org
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to the polarity of its environment and binding of a CPM-labeled
protein to an unlabeled partner usually results in a large increase
in CPM fluorescence. CPM is thiol-reactive and can attach to one
of the many Cys side chains distributed throughout the catalytic
and C-terminal domains along with one in the EF hand region.
We have previously found labeling PLCb2 with a thiol reactive
probe does not affect its activity or G protein activation properties
[22]. Addition of binding partners to CPM-PLCb2 results in
a concentration-dependent increase in fluorescence intensity that
quantitatively gives identical affinities as FRET and qualitatively
by other methods (see [22,23]). We note that CPM is essentially
non-fluorescent in its unreacted form, and although addition of
excess protein to unreacted probe will increase its fluorescence, its
signal never exceeded 1% of the signal obtained for any of the
samples used in this study. We added freshly prepared and purified
c-synuclein to a solution of CPM- PLCb2.
We observed a systematic increase in CPM-PLCb2 intensity
(i.e. 3964%) when c-synuclein was incrementally added. No
changes in intensity were detected when dialysis buffer was
substituted for c-synuclein. An example of a fluorescence titration
curve is shown in Fig. 2 where the data were corrected for
background, which was less than 1% of the signal, and also for

MDA-MB-231 representing stage 4 breast cancer (see [11]). As
shown in Fig. 1a, the proteins are widely distributed through the
plasma membrane and cytoplasm with a low nuclear population.
Also, we find a moderate degree of colocalization of the
endogenous proteins and a Mander’s coefficient of 0.5560.05
was obtained for the proteins in both cell lines. This value can be
compared to a positive control of 0.9360.01 (n = 9) measured for
an eGFP-tagged protein that was immunostained with Alexa647,
and a negative control of 0.017+0.02 (n = 7) measured for an
eGFP-tagged protein with only Alexa647-secondary antibody
(Calizo and Scarlata, submitted).
To corroborate the colocalization studies suggesting cellular
association of c-synuclein and PLCb2, we carried out coimmunoprecipitation studies in MDA-MB231 cells. The results,
shown in Fig. 1b, support the idea that these proteins associate in
cells.

In vitro, c-synuclein binds to PLCb2 with high affinity
We characterized the interaction between c-synuclein and
PLCb2 by studying the association of these proteins in solution.
For these studies, we covalently attached the fluorescent probe
CPM onto purified PLCb2 (see Methods). CPM is highly sensitive

Figure 1. PLCb2 and c-synuclein associate in cells. A – Co-immunofluroescence studies showing the colocalization of c-synuclein (green) and
PLCb2 (red) in two breast cancer cell lines, MCF10A and MDA-MB-231. B- Co-immunoprecipation of endogenous c-synuclein and PLCb2 in MDA-MB231 cells.
doi:10.1371/journal.pone.0041067.g001

PLoS ONE | www.plosone.org

3

August 2012 | Volume 7 | Issue 8 | e41067

c-Synuclein Interacts with Phospholipase Cb2

dilution. Fitting the titration curve to a biomolecular dissociation
constant gives a Kd = 6.561 nM. This same binding constant is
obtained when the initial concentration of CPM- PLCb2 was
reduced from 2.0 to 0.5 nM (Kd = 7.862 nM) supporting the idea
that we are viewing a protein-protein association. Substitution of
the full length CPM-labeled enzyme with only its labeled Nterminal PH domain (CPM-PH-PLCß2) or with CPM-Rac1 (see
below) gave a smaller increase in intensity at much higher protein
concentrations suggesting that the affinities for these other proteins
is at least 50 fold weaker, and indicating that we are indeed
observing association of c-synuclein with proteins and not with the
CPM label itself.

Identification of the binding region between c-synuclein
and PLCß2
We tested whether c-synuclein would alter the interaction
between PLCb2 and its activators. Since different G protein
subunits associate to different regions of the enzyme, we first set
out to identify the PLCb2 domain where c-synuclein binds. Rac1
and Gßc bind to the N-terminal PH domain of PLCb2, and so we
measured the association of c-synuclein to a PLCb2 construct that
is missing the long ,400 amino acid C-terminal region (see [19]).
We find that c-synuclein binds to this truncated enzyme at a far
lower affinity than the whole enzyme (Fig. 3 top). This result,
along with the fluorescence titrations described above, suggests
that c-synuclein interacts primarily with the C-terminal region of
the protein.
PLCb2 has a calpain cleavage site that releases the entire Cterminal tail region and truncation can be seen by the shift in the
133.7 KDa enzyme electrophoresis band to ,80 and ,45 KDa
bands (see [24]). In Fig. 3 bottom we show that c-synuclein
protects PLCb2 from calpain digestion. We extracted the
100 KDa band obtained from calpain-digested PLCb2 and
analyzed this product by mass spectrometry. Comparing this
fragment to the undigested and c-synuclein – PLCb2 complex, we
find that c-synuclein binding protects PLCb2 from calpain

Figure 3. The C-terminus of PLCb2is required for strong csynulcein binding. Top – Association of c-synuclein to a C-terminal
truncated PLCb2 construct under identical conditions as in Fig. 2.
While the affinity cannot be accurately obtained since the titration
curve did not plateau, the estimated the minimum apparent
dissociation constant is given. Bottom – Calpain digestion of PLCb2
showing cleavage of the ,134 kDa enzyme into ,80 and ,45 kDa
fragments where identical amounts of PLCb2 were loaded onto each
lane. Note the protection of enzyme digestion in the presence of csynuclein.
doi:10.1371/journal.pone.0041067.g003

cleavage at residue 753. This residue lies in a region that connects
the C2 domain with the C-terminal tail.

c-Synuclein inhibits Gaqbut not Gßc association to
PLCß2
The studies above show that c-synuclein binds to the region of
PLCb2 that is close to the binding region of Gaqas indicated by
the recent crystal structure of a truncated PLCb3 construct
complexed with Gaq [25] and overlaps with the region required
for Gaqactivation [26]. Thus, we tested whether c-synuclein could
compete with Gaqfor PLCb2 association by two complementary
types of fluorescence titrations (Fig. 4A). In the first, we measured
the association between CPM-Gaq(GDP) and PLCb2 in the
absence and presence of a ten-fold excess of c -synuclein. In the
second, we added PLCb2 labeled with a non-fluorescent FRET
acceptor (Dabcyl) to CPM- Gaq(GDP) and measured their
association by the decrease in CPM donor fluorescence in the
presence and absence of c-synuclein. Both studies show a clear
inhibition of Gaq(GDP) – PLCb2 binding when c-synuclein is
present (Fig. 4A). Activation of Gaqresults in an ,20 fold
increase in affinity for PLCb2 [22], and we find that a ten-fold

Figure 2. PLCb2 and c-synuclein associate in solution. Normalized change in fluorescence intensity of 2 nM CPM- PLCb2in solution as
purified c-synuclein is added where the total intensity increase was
3964%. The data shown are corrected for dilution and background,
which was less than 1% of the signal, and are an average of 3 sets of
measurements.
doi:10.1371/journal.pone.0041067.g002
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Figure 4. c-Synuclein inhibits the binding of Gaqbut not Gßc or Rac1, to PLCß2. A – (left) Fluorescence titrations showing that 20 nM csynuclein inhibits the association of PLCb2 to 2 nM CPM-Gaq(GDP) as seen by the 2763% increase in CPM-Gaq fluorescence as PLCb2 is added (n = 4)
and (right) by the ability of 20 nM c-synuclein to prevent FRET when PLCb2 with a non-fluorescent energy transfer acceptor (DAB) is added to CPMGaq(GDP), n = 3. B– (left) Change in the intensity of 10 nM CPM-Gßc when 100 nM c-synuclein is added, when 10 nM PLCb2 is added, and when
100 nM c-synuclein and 10 nM PLCb2 are added, n = 2. (right) Change in the intensity of 2 nM CPM-Rac1(GDP) when 5 nM PLCb2is added, when
20 nM c–synuclein is added and when 5 nM PLCb2 and 20 nM c-synuclein were added.
doi:10.1371/journal.pone.0041067.g004

Thus, c-synuclein may form ternary complexes with Gßc-PLCb2
and Rac1-PLCb2 but not with Gaq-PLCb2.

excess c-synuclein has little, if any, affect on the association
between activated Gaqand PLCß2, (Kd = 0.360.2 nM without csynuclein and 0.960.3 with c-synuclein, p = 0.049).
We also determined whether c-synuclein could affect Gßc PLCb2 interactions. Although we could not detect changes in
Gßc-PLCb2 association in the presence of excess c-synuclein, we
found evidence that c-synuclein weakly associated to the GßcPLCb2 complex. When c-synuclein was added to CPM- Gßc, an
increase in intensity was observed and a further increase occurred
upon the addition of PLCb2 (Fig. 4B left). An increase in
intensity was also seen when c-synuclein was added to the GßcPLCb2 complex. These results indicate that c-synuclein may form
a ternary complex with Gßc- PLCb2. Identical results were
obtained with deactivated or activated Rac1 (Fig. 4B right).
PLoS ONE | www.plosone.org

c-Synuclein inhibits the activity of PLCß2, but not its
activation by G proteins
We determined the impact of c-synuclein on the activity of
PLCb2. These studies were carried out by measuring the changes
in PLCb2-catalyzed hydrolysis of 3H-PI(4,5)P3. We find that the
presence of c-synuclein decreases PLCb2 activity approximately 4
fold (Fig. 5). This decrease is more pronounced than the decrease
seen using a-synuclein [27].
Rac1 has been reported to activate PLCb2 by increasing its
affinity for lipid membranes [12] although this does not appear to
be the case in purified systems (Golebiewska & Scarlata,
5
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Figure 5. c-Synuclein inhibits the enzymatic activity PLCb2. (left) Change in 20 nM PLCb2 activity with increasing amounts of c-synuclein.
(right) Ratio of PLCb2 activity with increasing substrate in the presence and absence of 10 mM Ins(1,4,5)P3 showing that c-synuclein promotes
product inhibition.
doi:10.1371/journal.pone.0041067.g005

Gßc complex. In fact, the addition of Gßc to PLCb2 overcomes csynuclein inhibition so that when the ratios of PLCb2- csynuclein/PLCb2 as a function of c-synuclein are plotted, an
apparent activation is seen (Fig. 6). In contrast, c-synuclein
similarly inhibits PLCb2 and PLCb2-Rac1 in accord with the idea
that Rac1 may enhance activity by promoting membrane
interactions of the enzyme [14].

unpublished). Nevertheless, we determined whether c-synuclein
affected PLCb2 activity by altering its membrane interactions.
These studies were done by measuring changes in binding of
PLCb2 to large, unilamellar vesicles composed of PC/PS/PE at
a 1:1:1 molar ratio in the presence and absence of excess csynuclein. Membrane binding was monitored by the large increase
in fluorescence intensity of CPM- PLCb2 that occurs when the
enzyme binds to membranes (see [28]). We find that a fourfold
excess of c-synuclein (100 nM) does not affect the partition
coefficient for membrane binding of PLCb2 (45610 mM, n = 4
without c-synuclein versus 39618 mM, n = 3 with c-synuclein).
These data suggest that PLCb2 binds to membranes with a similar
affinity as the PLCb2- c-synuclein complex.
We have previously found that Gßc activates PLCb2 by
increasing the rate of release of Ins(1,4,5)P3 product [21]. With this
in mind, we determined whether c-synuclein inhibits PLCb2 by
inhibiting the release of product. We measured product inhibition
of PLCb2 and the PLCb2- c-synuclein complex as a function of
substrate (PI(4,5)P2) concentration. In the absence of product, csynuclein did not affect the change in PLCb2 with increasing
amount of substrate. However, in the presence of c-synuclein, we
find that Ins(1,4,5)P3 reduces the ability of PI(4,5)P2 to promote
activity (Fig. 5B). Our interpretation of these results is that csynuclein stabilizes an early or intermediate conformation of the
enzyme where product is bound more strongly in the active site.

Discussion
In this study, we have established a link between c-synuclein
expression and PLCb2 activation in cultured cells. While the
function of PLCb2 is to transform G protein signals into calcium
responses [29,30], little is known about the cellular function of csynuclein in neuronal cells, where it is highly expressed, or in
certain transformed cells (but see http://www.disprot.org/protein.
php?id = DP00630). A large over-production of c-synuclein in
breast cancer was first noted by Shi and coworkers who identified
it as the breast cancer specific gene protein 1, which was later
found to be c-synuclein [7]. Anticancer agents that target csynuclein have been designed [31]. Over-production of PLCb2
correlates with the severity of breast cancer [10,11]. Since PLCb2
mediates mitogenic, proliferative and migratory events through its
interactions with heterotrimeric and monomeric G proteins, we
reasoned that c-synuclein might not only bind PLCb2 and affect
its basal activity, but also affect G protein activation.
c-Synuclein is classified as an unstructured protein and has
several potential binding partners (see [32]). Thus, we first
determined whether PLCb2 is a natural binding partner of csynuclein in cultured cells. In these studies, we visualized the two
proteins by immunofluorescence in MCF 10A and MDA MB231
cells that mimic stage 1 and 4 breast carcinoma, respectively. We
find a high degree of colocalization in both cell lines, and
additionally, the protein coimmunoprecipate. Thus, c-synuclein
appears to be a cellular binding partner of PLCb2.
We have previously carried out studies that investigated the
interaction between another PLCb family member, PLCb1, and
a-synuclein [24]. Both proteins are highly expressed in neural
tissue. We found that the region of interaction between these
proteins is the same and that their cellular association prevents
calcium-stimulated degradation of the enzyme by the protease
calpain. While it is unclear whether calpain degradation plays an
important role in cells expressing c-synuclein, it is probable that c-

G proteins reverse c-synuclein inhibition of PLCß2
Our binding studies predict that c-synuclein should effect
activation of PLCb2 by Gaqby direct competition, but not by Gßc
or Rac1. We first tested this idea by measuring the ability of csynuclein to diminish activation of PLCb2 by Gaq. We found that
addition of an 80 fold excess of c-synuclein did not reduce the
activity of the PLCß2-Gaqcomplex, due to the very strong affinity
between PLCb2 and activated Gaq. However, because c-synuclein
inhibits PLCb2, the ratio of Gaq/PLCb2/c-synuclein activity
versus c-synuclein -PLCb2 shows an apparent activation (Fig. 6).
This apparent activation is due to the ability of Gaq(GTPcS) to
displace c-synuclein from PLCb2 and cause a reversal in csynuclein inhibition as well as activation.
We also determined whether c-synuclein could affect activation
of PLCb2 by Gßc and Rac1. We found that even though csynuclein inhibits isolated PLCb2, it does not inhibit the PLCb2PLoS ONE | www.plosone.org
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Figure 6. c-Synuclein binding to PLCb2 results in an apparent increase in G protein activation. Top panels – Apparent activation of
20 nM PLCß2, as calculated by the ratio of the activity of PLCb2 complexed with Gaq(left) or Gßc (right) over PLCb2 alone, due to reversal of csynuclein by G protein subunits. Bottom – Activity studies showing that Rac1 does not interfere with inhibition of PLCb2.
doi:10.1371/journal.pone.0041067.g006

contrast, Gßc interacts with both the N-terminal pleckstrin
homology domain and the catalytic domain (see [13]) and can
reverse inhibition of PLCb2 by c-synuclein. This reversal is not
due to competition of c-synuclein binding by Gßc since csynuclein binds well to both PLCb2 and PLCb2-Gßc. Instead, our
data suggest that ternary complexes can form (Fig. 4). We
hypothesize that the mechanism through which Gßc activates the
enzyme does not allow for c-synuclein inhibition. Since Gßc and
c-synuclein inversely affect product release, (Fig. 5 and [36]), it is
possible that the conformational changes associated with product
release which are promoted by Gßc are preserved in the presence
of c-synuclein, and that displacement of c-synuclein may not be
required for reversal of inhibition. Thus, Gßc is a more potent
activator of PLCb2- c-synuclein than isolated PLCb2. More
studies are needed to understand the conformational changes
associated with product release. Regardless of the mechanism,
inhibition of PLCb2 by c-synuclein may not have significant
cellular effects since the basal activity of PLCb2 is low. However,
the ability of Gaqand Gßc to activate PLCb2 while simultaneously
reversing inhibition may lead to an apparently more robust
calcium signals.

synuclein will also protect PLCb2 from cleavage. This stabilization
could underlie the correlation between elevated PLCb2 levels with
increased c-synuclein expression making it difficult to quantify the
decrease in calcium release through PLCß with increased cellular
c-synuclein (Yerramilli et al., unpublished).
We characterized the affinity of c-synuclein-PLCb2 association
using purified proteins. Fluorescence studies show that the two
proteins associate strongly in solution with an affinity that is
slightly stronger than Gaq(GDP), Gßc and Rac1 but much weaker
than activated Gaq. Interestingly, the c-synuclein binding site
suggested by the calpain digestion studies overlaps with the
Gaqbinding site. We speculate that when c-synuclein expression is
very high, as in many carcinomas, PLCb2-c-synuclein may disrupt
preformed PLCb2-Gaq-receptor complexes in the basal state (see
[33,34]) or perturb the cellular localization of the enzyme.
However, upon activation, it is likely that Gaqcan displace csynuclein from PLCb2 allowing c-synuclein to homo- or heterooligomerize with other proteins. Importantly, activation of PLCb2
by G proteins to promote mobility and migration is preserved in
the presence of c-synuclein.
Our studies suggest that c-synuclein binding decreases the basal
activity of PLCb2 through a mechanism that appears to involve
product release rather than access to substrate by inhibition of
membrane interactions. Since Gaqbinds to the same region of the
PLCb2 as c-synuclein, it is not surprising that it reverses csynuclein inhibition by direct displacement. In contrast, Rac1
associates to the extreme N-terminus [35] and we find that this
association does not perturb c-synuclein binding or inhibition. In
PLoS ONE | www.plosone.org
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